Pharmacogenetic Tests in Reducing Accesses to Emergency Services and Days of Hospitalization in Bipolar Disorder: A 2-Year Mirror Analysis

Camilla Callegari, Celeste Isella, Ivano Caselli, Nicola Poloni, Marta Ielmini, Camilla Callegari, Celeste Isella, Ivano Caselli, Nicola Poloni, Marta Ielmini

Abstract

Despite the enormous costs associated to mood disorders', few studies evaluate potential cost saving from the use of pharmacogenetic tests (PGT). This study compares 12 months before the execution of the PGT versus 12 months after, in terms of number and days of hospitalization and accesses to emergency services, in a sample of 30 patients affected by bipolar disorder. Secondarily, the study gives an economic value to the data based on the diagnosis-related group (DRG). Patients included in the study were required to be aged ≥18 years, sign an informed consent, have a score of Clinical Global Impression item Severity (CGIs) ≥3, and have a discordant therapy compared to the PGT in the 12 months preceding it and a therapy consistent with it for the following 12 months. Cost saving has been evaluated by paired t-tests in a mirror analysis. Statistically significant differences in all the comparisons (p < 0.0001) emerged. Important cost saving emerged after the use of PGT (€148,920 the first year versus €39,048 the following year). Despite the small sample size and lack of a control group in this study, the potential role of PGT in cost saving for the treatment of bipolar disorder treatment emerged. To confirm this result, larger and clinical trials are needed.

Keywords: bipolar disorder; cost saving; mental health; mirror analysis; pharmacogenetic test; pharmacogenomics.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mirror analysis of the number of hospitalizations, days of hospitalizations, and number of times medical emergency services were accessed.

References

    1. Winner J.C., Carhart J.M., Altar A., Goldfarb S., Allen J.D., Lavezzari G., Parsons K.K., Marshak A.G., Garavaglia S., Dechairo B.M. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1-year prospective evaluation. Curr. Med. Res. Opin. 2015;31:1633–1643. doi: 10.1185/03007995.2015.1063483.
    1. Mrazek D.A., Hornberger J.C., Altar C.A., Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr. Serv. 2014;65:977–987. doi: 10.1176/appi.ps.201300059.
    1. Knoth R.L., Chen K., Tafesse E. Costs associated with the treatment of patients with bipolar disorder in a managed care organization. Psychiatr. Serv. 2004;55:1353. doi: 10.1176/appi.ps.55.12.1353.
    1. Stensland M.D., Jacobson J.G., Nyhuis A. Service utilization and associated direct costs for bipolar disorder in 2004: An analysis in managed care. J. Affect. Disord. 2007;101:187–193. doi: 10.1016/j.jad.2006.11.019.
    1. Sanchez-Martin A., Sanchez-Iglesias S., Garcia Berrocal B., Lorenzo C., Gaedigk A., Isidoro Garcia M. Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6. Pharmacogenomics. 2016;17:1291–1293. doi: 10.2217/pgs-2016-0105.
    1. Hall-Flavin D.K., Winner J.G., Allen J.D., Jordan J.J., Nesheim R.S., Snyder K., Drews M.S., Eisterhold L.L., Biernacka J.M., Mrazek D. Using a pharmacogenomics algorithm to guide the treatment of depression. Transl. Psychiatry. 2012;2:e172. doi: 10.1038/tp.2012.99.
    1. Gardner K.R., Brennan F.X., Scott R., Lombard J. The potential utility of pharmacogenetic testing in psychiatry. Psychiatry J. 2014;2014:730956. doi: 10.1155/2014/730956.
    1. Müller D.J., Kennedy J.L., Himmerich H. Future roles of pharmacogenomic testing and biomarkers in psychiatry. Int. Rev. Psychiatry. 2013;25:493. doi: 10.3109/09540261.2013.845376.
    1. Callegari C., Ielmini M., Bianchi L., Lucano M., Bertù L., Vender S. Antiepileptic drug use in a nursing home setting: A retrospective study in older adults. Funct. Neurol. 2016;31:87–93. doi: 10.11138/FNeur/2016.31.2.087.
    1. Ferrari M.B., Bolla E., Bortolaso P., Callegari C., Poloni N., Lecchini S., Vender S., Marino F., Cosentino M. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry Res. 2012;200:1014–1017. doi: 10.1016/j.psychres.2012.07.002.
    1. Bolla E., Bortolaso P., Ferrari M., Poloni N., Callegari C., Marino F., Lecchini S., Vender S., Cosentino M. Are CYP1A2*1F and *1C associated with clozapine tolerability? A preliminary investigation. Psychiatry Res. 2011;189:483–484. doi: 10.1016/j.psychres.2011.03.011.
    1. Diurni M., Baranzini F., Costantini C., Poloni N., Vender S., Callegari C. Metabolic side effects of second generation antipsychotics in drug-naïve patients: A preliminary study. Riv. Psichiatr. 2009;44:176–178.
    1. Albert U., Carmassi C., Cosci F., De Cori D., Di Nicola M., Ferrari S., Poloni N., Tarricone I., Fiorillo A. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: A systematized review. Int. Clin. Psychopharmacol. 2016;31:249–258. doi: 10.1097/YIC.0000000000000127.
    1. Poloni N., Callegari C., Buzzi A., Aletti F., Baranzini F., Vecchi F., Vender S. The Italian version of ISOS and RSQ, two suitable scales for investigating recovery style from psychosis. Epidemiol. Psichiatr. Soc. 2010;19:352–359. doi: 10.1017/S1121189X00000695.
    1. Poloni N., Diurni M., Buzzi A., Cazzamalli S., Aletti F., Baranzini F., Vender S. Recovery style, symptoms and psychosocial functioning in psychotic patients: A preliminary study. Riv. Psichiatr. 2013;48:386–392. doi: 10.1708/1356.15065.
    1. Caselli I., Poloni N., Ielmini M., Diurni M., Callegari C. Epidemiology and evolution of the diagnostic classification of factitious disorders in DSM-5. Psychol. Res. Behav. Manag. 2017;10:387–394. doi: 10.2147/PRBM.S153377.
    1. Casetta C., Montrasio C., Cheli S., Baldelli S., Bianchi I., Clementi E., Gambini O., D’Agostino A. Pharmacogentic variants in bipolar disorder with elevated treatment resistance and intolerance: Towards a personalized pattern of care. Bipolar Disord. 2019 doi: 10.1111/bdi.12763.
    1. Hall-Flavin D.K., Winner J.G., Allen J.D., Carhart J.M., Proctor B., Snyder K., Drews M.S., Eisterhold L.L., Geske J., Mrazek D. Utility of integrated pharmacogenomics testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet. Genom. 2013;23:535–548. doi: 10.1097/FPC.0b013e3283649b9a.
    1. Ielmini M., Poloni N., Caselli I., Espadaler J., Tuson M., Grecchi A., Callegari C. The utility of pharmacogenetic testing to support the treatment of bipolar disorder Open Access. Pharmgenomics Pers. Med. 2018;11:35–42. doi: 10.2147/PGPM.S160967.
    1. Ielmini M., Poloni N., Caselli I., Diurni M., Grecchi A., Callegari C. The role of pharmacogenetic testing in the treatment of bipolar disorder: Preliminary results. Minerva Psichiatr. 2018;59:10–15. doi: 10.23736/S0391-1772.17.01954-9.
    1. Benitez J., Jablonski M.R., Allen J.D., Winner J.G. The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes. Appl. Transl. Genom. 2015;5:47–49. doi: 10.1016/j.atg.2015.03.001.
    1. Herbild L., Bech M., Gyrd-Hansen D., Christensen M., Werge T., Nielsen K.A. Do guidelines recommending pharmacogenetic testing of psychiatric patients affect treatment costs and the use of healthcare services? Scand. J. Public Health. 2011;39:147–155. doi: 10.1177/1403494810393300.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj